Table 1.
Clinical characteristics of participants for antibody array.
| COPD | COPD with PH | P -value | |
|---|---|---|---|
| N | 4 | 4 | - |
| Sex (male) | 4 (100%) | 4 (100%) | - |
| Age (year) | 63.75 ± 3.84 | 63.50 ± 2.60 | 0.96 |
| Smoking (pack-year) | 23.75 ± 5.54 | 31.25 ± 1.25 | 0.24 |
| NT-pro-BNP (pg/mL) | 31.90 ± 23.83 | 121.6 ± 88.23 | 0.10 |
| Predicted FEV1 (%) | 37.60 ± 6.06 | 34.90 ± 4.70 | 0.74 |
| EF (%) | 72.50 ± 0.03 | 70.00 ± 0.03 | 0.57 |
| RAD (mm) | 28.00 ± 1.58 | 35.50 ± 1.32 | 0.01* |
| RVD (mm) | 20.50 ± 1.19 | 24.50 ± 0.65 | 0.025* |
| PASP (mmHg) | 29.50 ± 2.10 | 51.25 ± 4.11 | <0.01** |
NT-pro-BNP, N-terminal pro-brain natriuretic peptide; predicted FEV1, predicted forced expiratory volume in 1 s; EF, ejection fraction; RVD, the right ventricular diameter measured by Doppler Echocardiography, RAD, the transverse diameter of right atrium measured by Doppler Echocardiography; PASP, systolic pulmonary arterial pressure measured by Doppler Echocardiography.
*
P < 0.05 vs. COPD group,
**
P < 0.01 vs. COPD group, absolute case numbers (% of cases in group). Values are shown as n (%) or mean ± SEM.